Canada Markets closed

Hemostemix Inc. (HMTXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1097-0.0092 (-7.73%)
At close: 09:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1189
Open0.1097
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1097 - 0.1097
52 Week Range0.1037 - 0.4671
Volume1,000
Avg. Volume3,737
Market Cap6.489M
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.1050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics

    Calgary, Alberta--(Newsfile Corp. - January 21, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a Global Master Services Agreement with My Next Health ("MNH"), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit.My Next Health Inc. ("MNH") is the world's leading patient-based AI-functional genomic medical analysis company. ...

  • Newsfile

    Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 Diabetes

    Calgary, Alberta--(Newsfile Corp. - January 11, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a contract with Dr. James Shapiro, University of Alberta, Edmonton and will complete a transfer ACP-01 to Dr. Shapiro's laboratory. The combination of ACP-01, an autologous angiogenic cell precursor that has demonstrated improvement of angiogenesis in the heart and limbs of individuals who suffer from ischemia, ...

  • CNW Group

    Virtual Conference for Life Sciences Companies Broadcast Live December 16th

    Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.